아이엠 캐너비스(IMCC) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

IMCC

IM Cannabis Corp

7월 28일 1:07 PM ET (한국 7/29 02:07)

$0.11

-0.01 ▼ -11.17%

아이엠 캐너비스(IMCC) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$1M

스몰캡

P/E

배당수익률

없음

52주 위치

저점 -4% · 고점 -97%

애널리스트

매수

Fundamental health

vs. 미분류 초소형주· based on 2 axes

수익성

산출 불가 (적자)

성장

Top 28%

밸류에이션

데이터 부족

재무 안정

Top 100%

Index ⓘ	-	P/E ⓘ	-	EPS (ttm) ⓘ	-1.82	Insider Own ⓘ	35.15%	Shs Outstand ⓘ	6.2M	Perf Week ⓘ	-19.19%
Market Cap ⓘ	0.00B	Forward P/E ⓘ	-	EPS next Y ⓘ	-	Insider Trans ⓘ	-	Shs Float ⓘ	2.0M	Perf Month ⓘ	-23.88%
Enterprise Value ⓘ	0.01B	PEG ⓘ	-	EPS next Q ⓘ	-	Inst Own ⓘ	0.12%	Short Float ⓘ	10.7%	Perf Quarter ⓘ	-62.18%
Income ⓘ	-0.01B	P/S ⓘ	0.03	EPS this Y ⓘ	-	Inst Trans ⓘ	-56.12%	Short Ratio ⓘ	0.04	Perf Half Y ⓘ	-92.04%
Sales ⓘ	0.04B	P/B ⓘ	-	EPS next 5Y ⓘ	-	ROA ⓘ	-41.53%	Short Interest ⓘ	0.21M	Perf YTD ⓘ	-92.27%
Book/sh ⓘ	-0.58	P/C ⓘ	1.17	EPS past 3/5Y ⓘ	74.93% 43.53%	ROE ⓘ	-25089.74%	52W High ⓘ	-96.57% ($3.13)	Perf Year ⓘ	-96.18%
Cash/sh ⓘ	0.09	P/FCF ⓘ	-	Sales past 3/5Y ⓘ	-2.09% 27.02%	ROIC ⓘ	-	52W Low ⓘ	-3.59% ($0.11)	Perf 3Y ⓘ	-97.77%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	-	EPS Y/Y TTM ⓘ	-24.22%	Gross Margin ⓘ	15.08%	Volatility(W/M) ⓘ	8.14% 10.15%	Perf 5Y ⓘ	-99.96%
Dividend TTM ⓘ	-	EV/Sales ⓘ	0.29	Sales Y/Y TTM ⓘ	-6.14%	Oper. Margin ⓘ	-19.86%	ATR (14) ⓘ	0.02	Perf 10Y ⓘ	-
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.47	EPS Q/Q ⓘ	-550.89%	Profit Margin ⓘ	-27.2%	RSI (14) ⓘ	26.87	Recom ⓘ	2
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	0.55	Sales Q/Q ⓘ	-27.37%	SMA20 ⓘ	-25.89% ($0.15)	Beta ⓘ	2.08	Target Price ⓘ	$6
Payout ⓘ	-	Debt/Eq ⓘ	-	Earnings ⓘ	2026/5/13	SMA50 ⓘ	-46.86% ($0.21)	Rel Volume ⓘ	0.53	Prev Close ⓘ	$0.12
Employees ⓘ	44	LT Debt/Eq ⓘ	-	EPS/Sales Surpr. ⓘ	-	SMA200 ⓘ	-87.75% ($0.9)	Avg Volume(3M) ⓘ	5.19M	Price ⓘ	$0.11
IPO ⓘ	2020/5/20	Option/Short ⓘ	No/Yes			Trades ⓘ	1631	Volume ⓘ	2,766,052	Change ⓘ	-11.17%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 IM Cannabis Corp (IMCC) Investment Analysis

What kind of company is IM Cannabis Corp?

아이엠 캐너비스(IMCC)

Healthcare · Drug Manufacturers - Specialty & Generic

Small-Cap — Low Volume, High Volatility

🍃 Medical cannabis platform. Operating in Israel and Germany. C4.7M revenue in 2025. 134% growth in Germany. Considering entry into the U.S. market.

Learn more about IM Cannabis Corp →

Market Cap

$0.0B

Approx. KRW 0.0 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank5875

Employees44people

IPO2020/05/20

Current Price$0.11 ≈ 151원

NASD · Israel

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 13일 (수) · 장 마감 후

🔔 Earnings release 2025년 11월 13일 (목) · 장 시작 전

Is it profitable?

Both profitability & finances need caution

Review management risk carefully before investing

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-19.9%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

-27.2%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

15.1%

✓ 평균

My positionMid-range

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Bottom 34%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

-25089.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

ROA

Annual earnings relative to total company assets

-41.5%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Financial health — Debt & liquidity burden

Current Ratio

Liquid assets available to cover liabilities due within a year

0.55

✓ 매우 부진

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 2.47

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.47

✓ 매우 부진

My positionBottom 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic Median 1.68

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$6.00

현재가 대비 +5354.5%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth

Mid-range within the industry

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+74.9%

우수

My positionTop 25%

Low range Average High range

미분류 초소형주 Median 25.4% · Top 13%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+43.5%

우수

My positionTop 25%

Low range Average High range

미분류 초소형주 Median 14.6% · Top 22%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+27.0%

우수

My positionTop 5%

Low range Average High range

미분류 초소형주 Median 2.8% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-27.4%

부진

My positionBottom 25%

Low range Average High range

미분류 초소형주 Median -2.6% · Bottom 23%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -168%p below the market

IMCC -100.0% · S&P 500 +68.4%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-168.3%p

Significantly behind the market

vs Health Care (XLV)

-124.5%p

Significantly behind the sector average

1-year basis

vs S&P 500

-112.2%p

Significantly behind the market

vs Health Care (XLV)

-115.9%p

Significantly behind the sector average

Rank among peers

5-year return Bottom 13% Based on 28 peers

1-year return Lowest among peers Based on 36 peers

Current position within 52-week range

Low (-3.6%p) High (-96.6%p)

Current price is 3.6% above the 52-week low and 96.6% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-90.8%

Annualized volatility

122.8%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

Current price $0.11 fell below the lower band ($0.12). Selling pressure excessive; worth watching for a short-term bounce. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD -0.023 · Signal -0.024 · Hist 0.001. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔵

Current diagnosis · 2026-07-27

Oversold zone — rebound potential

RSI 29.8 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 14.3.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Sales

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

🧾 Vs. Sales Cheap

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

0.03x

✓ Very cheap

My positionTop 5%

Low range Average High range

Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Top 1% — relatively cheap within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

Analyst target price (reference)

$6.00 vs. current price +5354.5%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 초소형주

Who owns it?

Ownership backdrop is unfavorable

Institutional net selling -56.1% · Short interest elevated 10.7% · Short interest up +10.2pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

0.0%

Insiders little change

🏦 Institutions (funds & investors)

-56.1%

Institutions large net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 0.1%

Retail-led

Healthcare 초소형주 Median 14.2%

🧑‍💼 Insiders 35.1%

Founder/management large holders (strong skin-in-the-game)

Healthcare 초소형주 Median 16.1%

👤 Retail investors (estimated) 64.7%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

10.7%

Somewhat high

Healthcare 초소형주 Median 3.9%

Past 90 days 📈 +10.2%p increase

Short interest days to cover

0.0 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 6.2M주

Float (tradable shares) 2.0M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
IMCC This Stock	$1.0M	-	-	-25089.74% ▼	-	-11.2%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 아이엠 캐너비스(IMCC)?

아이엠 캐너비스(IMCC) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of IMCC?

The market cap of IMCC is approximately $1M, ranking 5,875 within its sector.

What is the 52-week high and low for IMCC?

IMCC has recorded a 52-week high of $3.13 and a low of $0.11.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.